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OBJECTIVE: Non-pituitary tumors have been reported in a subset of patients harboring germline mutations in the aryl hydrocar-
bon receptor-interacting protein (AIP) gene. However, no detailed investigations of non-pituitary tumors of AIP-mutated patients 
have been reported so far.
PATIENTS: We examined a MEN1- and p53-negative mother-daughter pair with acromegaly due to somatotropinoma. Subsequently, 
the mother developed a large virilizing adrenocortical carcinoma and a grade II B-cell non-Hodgkin’s lymphoma.
DESIGN: Mutational analysis was performed by automated sequencing. Loss-of-heterozygosity (LOH) analysis was carried out by 
sequencing and microsatellite analysis. AIP expression was assessed through quantitative PCR (qPCR) and immunohistochemistry. 
RESULTS: The functional inactivating mutation c.241C>T (R81X), which blocks the AIP protein from interacting with phos-
phodiesterase 4A (PDE4A), was identified in the heterozygous state in the leukocyte DNA of both patients. Analyzing the tumoral 
DNA revealed that the AIP wild-type allele was lost in the daughter’s somatotropinoma and the mother’s adrenocortical carcinoma. 
Both tumors displayed low AIP protein expression levels. Low AIP gene expression was confirmed by qPCR in the adrenocortical 
carcinoma. No evidence of LOH was observed in the DNA sample from the mother’s B-cell lymphoma, and this tumor displayed 
normal AIP immunostaining.
CONCLUSIONS: Our study presents the first molecular analysis of non-pituitary tumors in AIP-mutated patients. The finding 
of AIP inactivation in the adrenocortical tumor suggests that further investigation of the potential role of this recently identified 
tumor suppressor gene in non-pituitary tumors, mainly in those tumors in which the cAMP and the 11q13 locus are implicated, is 
likely to be worthwhile.
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INTRODUCTION
Acromegaly/gigantism is characterized by excess of 
growth hormone (GH) largely due to GH-secreting pituitary 
adenomas.1 Although most cases are sporadic, familial forms 
may occur in association with inherited syndromes such 
as Multiple Endocrine Neoplasia type 1 (MEN1), Carney 
complex (CNC), pituitary adenoma predisposition (PAP) and 
familial isolated pituitary adenoma (FIPA), which includes 
isolated familial somatotropinoma (IFS).2-4 
Germline mutations and somatic inactivation of the 
aryl hydrocarbon receptor- interacting protein (AIP) gene 408
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have been recently identified in patients with PAP.2 The 
role of AIP in FIPA patients has been confirmed, and more 
than thirty different AIP inactivating mutations have been 
identified throughout the gene.5 GH-, GH/PRL- and PRL-
secreting pituitary adenomas are the most common clinical 
features of AIP mutation carriers, although ACTH-secreting 
and non-functioning pituitary adenomas have also been 
reported.5,6 AIP mutations account for approximately 15% 
of families with FIPA and 50% of IFS families.3,5 While 
AIP mutations appear to be very rare in cases with sporadic 
pituitary disease,7,8,9 they are more frequently found in 
children and adolescents with GH-secreting tumors, even in 
the absence of family history.10
Although no systematic clinical surveys of non-pituitary 
neoplasia have been reported, concomitant non-pituitary 
tumors, including thyroid, adrenal and MEN1-related 
tumors were reported in a subset of AIP mutation-positive 
PAP and FIPA families10,11 and Prof. Albert Beckers, FIPA 
Meeting, Liège 2009 (unpublished data). The fact that AIP 
interacts with phosphodiesterases type 4A (PDE4A) and 
type 2A (PDE2A) implicates this gene in the cyclic AMP 
(cAMP) signaling cascade,12,13 a cellular pathway known 
to be disrupted in pituitary, but also in thyroid and adrenal 
tumorigenesis.14,15 Furthermore, AIP is widely expressed, 
which may argue in favor of a potential involvement of 
this gene also in non-pituitary tumors. Thus, one may 
hypothesize that mutations in AIP may also predispose 
patients to a broader spectrum of endocrine tumors. 
However, no genetic investigations of non-pituitary 
tumors in AIP-mutated patients have been performed to 
date. In this study, we investigated tumoral samples from 
a somatotropinoma, an adrenocortical carcinoma and a 
grade II B-cell non-Hodgkin’s lymphoma from a mother-
daughter pair with IFS who harbor a functional AIP germline 
mutation.
SUBJECTS
We investigated the germline and somatic status of AIP 
in a previously reported Brazilian family (mother-daughter 
pair)16 with early-onset acromegaly (at 25 years and at 14 
years, respectively) due to invasive pituitary macroadenomas 
who have been followed in our institution for the last decade. 
This family has been recently included in the ongoing 
genetic screening program for Multiple Endocrine Neoplasia 
at the Endocrine Genetics Unit laboratory at the University 
of São Paulo School of Medicine.17-24 Since the initial 
report of a GH-secreting pituitary adenoma, the index case 
(mother) subsequently developed a virilizing adrenocortical 
carcinoma and a grade II B-cell non-Hodgkin lymphoma. 
Because MEN1 and p53 mutations had been previously 
excluded in this case,16,25 we hypothesized that loss of the 
AIP gene could be implicated.
CLINICAL FEATURES
The index patient was diagnosed with acromegaly due 
to a pituitary macroadenoma at 25 years of age (1986). 
MEN1 and CNC syndromes were ruled out given the 
absence of the characteristic biochemical and clinical 
features of these syndromes (such as hyperparathyroidism 
and enteropancreatic tumors for MEN1 and spotty skin 
pigmentation, cutaneous myxomas and Cushing’s syndrome 
for CNC). She underwent transsphenoidal surgery followed 
by radiotherapy and exhibited persistently normal basal 
serum levels of GH and insulin-like growth factor-1 (IGF-1) 
after surgery. At present (48 years old), GH and IGF-1 levels 
remain within the normal range, and the pituitary MRI was 
normal, indicating that she had been cured of her pituitary 
disease. 
Thirteen years after pituitary surgery (1999), she presented 
with virilization and secondary amenorrhea associated with 
high serum levels of total testosterone (538 ng/dL; normal 
range, 15-80 ng/dL) and dehydroepiandrosterone sulfate 
(DHEA-S) (>10,000 ng/mL; normal range, 350-4300 ng/mL).   
An abdominal CT scan revealed a large heterogeneous mass 
(9.0 cm x 8.9 cm) in the right adrenal gland compressing 
the vena cava and the lower portion of the liver. The tumor 
was surgically excised en bloc without rupturing the organ 
capsule through a classic lobotomy, and right nephrectomy 
and extensive resection of local lymph nodes were performed. 
The histopathological analysis ruled out the invasion of local 
lymph nodes, liver or vena cava, and the tumor was staged as 
MacFarlane-II and Weiss-III (high nuclear grade, absence of 
clear cells and diffuse architecture), indicating adrenocortical 
carcinoma. There has been no biochemical or imaging 
evidence of tumor recurrence during 10 years of post-surgical 
follow-up (1999-2009). 
At the age of 42 (2001), the patient developed an 
apparently indolent grade 2 (WHO classification) slow-
growing follicular B-cell non-Hodgkin lymphoma. The 
immunophenotype was ascertained by immunohistochemical 
studies of lymph node biopsy samples. The samples were 
positive for anti-BCL-2, CD10, CD20 and CD68 antibodies 
and negative for CD3 (in the follicles). 
The patient also presented two solid thyroid nodules of 
7 mm and 11 mm in size, without adenomegaly, that had 
been identified in previous cervical ultrasonograms (1999). 
Pelvic imaging studies (2001) showed ovaries of 5.1 cm and 
7.8 cm, respectively, two ovarian cysts (4.7 cm and 5.5 cm) 
and periaortic, cava-aortic and iliac lymph nodes that were 
enlarged by up to 2 cm. She underwent a hysterectomy due 409
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to adenomyosis and an oophorectomy (right ovary) due to 
enlarged follicle cysts. 
Family history
The index patient has two daughters (dizygotic twins) 
and one son (Figure 1A). One of the female twins was 
evaluated at 14 years of age. She was 167 cm tall and 
presented with mild acromegaloid features but no signs 
of gigantism. The GH and IGF-1 serum levels were high, 
whereas prolactin was normal. An MRI revealed a large 
pituitary adenoma with suprasellar extension, as well 
as an invasion of the cavernous and sphenoid sinuses. 
The tumor was resistant to somatostatin analog therapy. 
The patient subsequently underwent two transcranial 
surgeries, one of which involved a transcavernous approach. 
Histopathological immunohistochemistry analyses indicated 
that the pituitary adenoma was positive for GH. No clinical 
and biochemical features of the MEN1 and CNC syndromes 
were observed in this patient. She has been followed up 
Figure 1 - Genealogy: identification of a functional AIP mutation that may disrupt the cAMP signaling pathway. A - The index patient developed acromegaly, 
adrenocortical carcinoma and B-cell lymphoma. One of her daughters had acromegaly due to a large and invasive somatotropinoma. B - The known AIP 
functional mutation c.241C>T (R81X)28 was identified in genomic DNA samples from both patients (mother and daughter) with acromegaly but not in the 
three unaffected family members.410
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periodically since 2000, and any adrenal involvement has 
been ruled out by clinical assessment, determination of 
adrenal steroid levels and imaging studies (abdominal CT 
scans). The other female twin and the son were clinically 
and biochemically normal.
The index patient reported that one of her sisters also 
exhibited thyroid nodules and that her mother and another 
sister had ovarian cysts. These individuals were not available 
for clinical assessment. 
GENETIC (NON-AIP) FEATURES
MEN1 gene
As previously reported, the index patient did not harbor a 
germline MEN1 mutation; however, she and her acromegalic 
daughter share 13 microsatellite loci at chromosomal region 
11q13.16
P53 gene
Furthermore, the index patient did not have a germline 
or somatic R337H TP53 mutation, which is commonly 
identified in children but less frequently identified in adult 
patients with adrenocortical neoplasia in southern Brazil.25
TUMORS
Both paraffin blocks and frozen tissue samples of the 
daughter’s GH-secreting pituitary adenoma and the mother’s 
adrenocortical tumor and B-cell non-Hodgkin lymphoma 
were available for study. Samples from the thyroid and 
ovarian tissues and the mother’s somatotropinoma were not 
available.
METHODS
The present study was approved by the local ethics 
committee (Cappesq) of our institution (protocol 0437/08). 
All patients and control subjects gave written informed 
consent.
AIP germline mutation analysis
Genomic DNA was isolated from the peripheral blood 
using a standard salting-out protocol, and PCR reactions 
were performed as previously described.2 Both DNA strands 
were sequenced from purified PCR products using Big Dye 
Terminator v3.1 (Applied Biosystems, Foster City, CA) and 
an automated sequencer (ABI Prism 3130xl DNA Analyser, 
Applied Biosystems).
Loss-of-heterozygosity analysis
Two different approaches (intragenic and extragenic) 
were used to verify whether the AIP wild-type allele was 
lost in the tumors. The mother’s somatotropinoma and 
thyroid neoplasm were not available for study. We performed 
PCR amplification, automated sequencing and haplotyping 
analysis using the D11S1258-11q13 microsatellite marker 
located close (67,069,747-67,069,958 bp, Ensembl) to 
the AIP gene 11q13.3 locus (67,007,097-67,015,150 bp, 
Ensembl). 
Quantitative mRNA analysis
A commercially available RNA/cDNA pool of normal 
adrenals (n=61), normal pituitary and normal adrenal tissues 
obtained from autopsies (Clontech, Palo Alto, CA) were 
used as controls. Quantitative PCR (qPCR) was performed 
with an ABI Prism 7700 Sequence Detector using the 
TaqMan Gene Expression Assays (Hs00610222_m1 for 
AIP and 43263 for β-actin) following the manufacturer’s 
instructions (Applied Biosystems). A cycle threshold (CT) 
value in the linear range of amplification was selected for 
each sample in triplicate and normalized to the β-actin 
expression levels. The relative expression levels were 
analyzed using the 2-ΔΔCT method,26 where ΔΔCT is the 
difference between the selected ΔCT value of a particular 
sample and the ΔCT of a pool of normal adrenals. 
AIP immunohistochemistry
The  slides  were  deparaffinized,  hydrated  and 
subsequently incubated in a 10 mM citrate buffer (pH 6.0) 
on a steamer for 40 min at 95 ºC. After several washes, each 
set of slides was incubated overnight with an anti-ARA9/
AIP monoclonal primary antibody (clone 35-2, Novus 
Biologicals, Littleton, CO), and then with the Novolink 
(Vision Biosystems™, Victoria, Au) secondary peroxidase 
short polymer system. Detailed information on qPCR and 
immunohistochemistry protocols can be obtained upon 
request.
RESULTS
AIP germline status in the IFS patients
A heterozygous nucleotide change c.241C>T (R81X) 
in exon 2 of AIP was identified in genomic DNA samples 
from the two acromegaly patients (mother and daughter) 
(Figure 1). The R81X is a known functional mutation that 
codes for a truncated protein lacking the tetratricopeptide 411
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repeat (TPR) carboxy terminal domains, which are essential 
for AIP to bind to the aryl hydrocarbon receptor (AHR) and 
heat shock 90 (HSP90).12,27 Previous in vitro studies of the 
R81X mutation have shown that it blocks the interaction of 
wild type AIP and phosphodiesterase type 4A (PDE4A), 
potentially disrupting the cAMP cascade.28 
AIP somatic status in the somatotropinoma, adrenocor-
tical tumor and B-cell non-Hodgkin lymphoma
Sequencing the AIP gene in the tumoral DNA samples 
revealed a complete loss of the remaining wild-type allele 
“C” in both the pituitary and adrenocortical tumors (Figures 
2B, 3B). Samples from the adrenocortical tumor and B-cell 
non-Hodgkin lymphoma were analyzed with the AIP-
flanking microsatellite marker D11S1258, and LOH was 
confirmed in the adrenocortical tumor (Figure 3B). However, 
the lymphoma maintained heterozygosity at the AIP locus 
(Figure 4).
AIP gene expression in normal adrenals and the adre-
nocortical tumor of the IFS AIP-mutated patient
The mean Ct values of AIP and β-actin in the pool of 
normal adrenal samples were 25.42 and 22.49, respectively, 
while in the adrenocortical carcinoma of the IFS AIP-
mutated case, the values were 31.53 and 27.28, respectively. 
Using the 2-ΔΔCT method to determine relative expression, 
we observed decreased AIP expression in the adrenocortical 
carcinoma in comparison to the pooled normal adrenals 
(2-ΔΔCT = 0.48) (Figure 3C). This finding is in accordance 
with our analysis of the somatic status of AIP, which showed 
Figure 2 - Loss of AIP in the familial somatotropinoma. A - The MRI of the index patient’s daughter revealed a large and invasive pituitary adenoma (so-
matotropinoma) that was resistant to treatment with a somatostatin analog. She inherited the heterozygous R81X AIP germline mutation (Fig. 1B) from the 
index case. B - The sequence analysis of AIP in tumoral DNA samples revealed that only the R81X-mutated allele (t) was present in the somatotropinoma, 
indicating somatic loss and inactivation of wild-type AIP. C - The immunohistochemical analysis showed AIP protein expression in the normal pituitary 
and a GH-secreting pituitary adenoma of a patient with sporadic acromegaly without AIP mutation. The somatotropinoma of the patient harboring the R81X 
germline mutation and the somatic loss of the gene presented low AIP protein expression.412
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LOH in this non-pituitary (adrenocortical) tumor, as shown 
in Figure 3B. 
AIP immunohistochemistry
Pituitary tissue: Decreased AIP immunostaining 
was observed in the pituitary adenoma from the daughter 
harboring the R81X germline mutation, while intense 
cytoplasmic AIP positivity was observed in the normal 
pituitary glands obtained from autopsy samples and in a 
somatotropinoma from a patient with sporadic acromegaly 
without the AIP germline mutation (Figure 2C). 
Adrenal tissue: The mother’s adrenocortical carcinoma 
showed positive staining for Melan A and 35betaH11 (data 
not shown), which are two markers of adrenal cortical 
differentiation used as positive controls, and complete loss 
of AIP immunoreactivity (Figure 3D). Moderate and strong 
staining of AIP-positive cells was observed in normal adult 
(Figure 3D) and infant adrenal tissue, respectively.
Grade II B-cell non-Hodgkin lymphoma: Normal AIP 
protein expression was observed in the index patient’s B-cell 
lymphoma when compared to the amygdala lymphoid tissue, 
which was used as a control (Figure 4).
Figure 3 - Loss of AIP in the adrenocortical tumor. A - An abdominal imaging scan of the index case when she presented with virilization and high serum 
levels of adrenal steroids. The scan revealed a large heterogeneous mass (9.0 cm x 8.9 cm) in the right adrenal gland, which was surgically excised and 
histopathologically classified as adrenocortical carcinoma. B - Sequence and microsatellite (D11S1258 AIP-flanking marker) analyses of DNA samples from 
the tumor revealed loss of the wild-type AIP allele. C - The 2-ΔΔCT method was used to compare AIP mRNA expression in pooled normal pituitary glands 
(Ct AIP=25.66, Ct β-actin=24.24), pooled normal adrenal glands (Ct AIP=25.42; Ct β-actin=22.49) and the adrenocortical carcinoma from the index case, 
in whom the AIP wild-type allele was lost (Ct AIP=31.53, Ct β-actin=27.28). The mean Ct value of the normal adrenal pool was used as a reference (1.0), 
by comparison, there was decreased AIP expression in the adrenocortical carcinoma (0.48). D - Immunohistochemistry using the AIP antibody showed low/
moderate staining in a normal adrenal gland obtained from autopsy. A complete loss of AIP immunoreactivity was observed in the adrenocortical carcinoma 
from the index patient, which stained positive for Melan A and 35betaH11, which were used as positive controls.413
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Figure 4 - Maintenance of heterozygosity and positive AIP immunostaining in the B-cell non-Hodgkin lymphoma of the R81X AIP mutated IFS patient.
DISCUSSION
Rare extra-pituitary tumors have been identified in PAP/
FIPA patients harboring AIP mutations. Mutant AIP cannot 
interact with cAMP-specific PDE4A and therefore is likely 
to disrupt the cAMP signaling pathway.12,27,28 This pathway 
has been previously implicated in both pituitary and non-
pituitary tumorigenesis through defects in the PRKAR1A,29 
GNAS1,30 PDE11A31 and PDE8B32 genes. Thus, further 
investigation of the role of AIP in these concomitant non-
pituitary tumors is warranted. Here, we present the first 
somatic investigations of pituitary and non-pituitary tumors 
(somatotropinoma, adrenocortical and grade II B-cell non-
Hodgkin lymphoma) in a family harboring an AIP germline 
mutation.
We initially found that both the mother and daughter with 
acromegaly harbored a functional cAMP pathway-disrupting 
germline mutation in AIP (c.241C>T; R81X). Through 
sequence analysis of tumoral samples, we showed that the 
remaining wild-type allele C was lost in the daughter’s GH-
secreting pituitary adenoma and the mother’s adrenocortical 
carcinoma. LOH was confirmed by analyzing the D11S1258 
repeat marker located at the AIP locus (11q13.3). In 
addition, we observed decreased AIP mRNA and protein 
expression in the adrenocortical tissue when compared to 
normal controls (Figure 3C and 3D). In contrast, normal 
AIP protein expression and no LOH for 11q13.3 locus were 
verified in the B-cell non-Hodgkin lymphoma from the 
same patient (Figure 4). According to the Knudson two-
hit model, these findings confirm that AIP plays a tumor 
suppressor role in the pituitary, as previously reported,2,3,4,8 
and suggest for the first time that AIP may also be implicated 
in non-pituitary tumorigenesis. Interestingly, previous 
genetic studies have strongly suggested the existence of 
an as-yet-unidentified tumor suppressor gene at 11q13 that 
is implicated in adrenocortical tumorigenesis.33-35 We are 
expanding the analysis of AIP to a large cohort of Brazilian 
sporadic adrenocortical tumors.
Of note, a reported female patient harboring a germline 
nonsense AIP mutation, L210X, developed a broad panel 
of neoplasias involving the pituitary, adrenocortical and 
thyroid glands;10 this previous report suggests that the 
tumor susceptibility was similar to that observed in our 
index case. The L201X-mutated patient presented with 
secondary amenorrhea at the age of 25 and was diagnosed 
with acromegaly at 27 years of age. Subsequently, she 
developed a 19-mm non-secretory adrenocortical adenoma 
and a 4-cm thyroid adenoma. Georgitsi et al. studied 91 414
CLINICS 2010;65(4):407-15 Loss of AIP gene in tumors of FIPA patients
Toledo RA et al.
Copyright © 2010 CLINICS
cases of “MEN1-related” tumors without MEN1 mutation, 
and they detected 2 cases (2.2 %) with AIP germline 
mutations.11 However, no details of the clinical manifestation 
of the mutated patients were provided, and it is not clear 
if they were FIPA/IFS patients. Recently, patients with 
AIP mutations and thyroid disorders, including nodular 
goiters, follicular adenomas and follicular and papillary 
thyroid carcinomas, have been described (Prof. Beckers, 
FIPA Workshop 2009, Liège, unpublished data; Drs. 
Outi Vierimaa and Pasi Salmela, University of Helsinki, 
Marianthi Georgitsi’s PhD Thesis). In these cases, it is not 
known whether the non-pituitary tumors occurring in the 
FIPA cases harboring an AIP mutation were related to the 
primary germline event. Further molecular investigations in 
FIPA/IFS patients with non-pituitary tumors would improve 
our knowledge of the tumoral susceptibility caused by AIP 
germline defects.
In conclusion, our study presents the first molecular 
analysis of non-pituitary tumors in patients harboring 
the AIP germline mutation. The finding of somatic AIP 
inactivation in the adrenocortical tumor of a AIP-mutated 
patient suggests that we should further investigate the role 
of this recently identified tumor suppressor gene in non-
pituitary tumors, especially those tumors in which cAMP 
and the 11q13 locus are implicated.
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